Remote clinical skin trials are a novel way of conducting skin research. Using lab grown 3D skin models and the replication of a volunteer’s microbiome, Labskin’s platform enables timely and cost-effective remote skin trials that do not require human volunteers. This is a safer, easier way for companies to test the efficacy of new treatments.
The primary care professional must remain involved throughout the trial and provide ongoing evaluation in conjunction with the protocol. Moreover, adult subjects must have at least one affected antecubital fossa (the target site). In addition, subjects must be 18 years of age and not have any unstable or uncontrolled medical conditions. If a subject has a chronic medical condition, such as diabetes or hypertension, they can be considered for the trial only after the medical investigator determines their suitability.
Clinical trials adhere to strict standards for data collection, and patients’ anonymity is ensured. A key feature of this type of study is blind randomisation, which helps reduce the impact of bias on the research. Skincare products that do not contain water are easier to test, because they do not require preservatives. However, testing water-based products is more expensive.
In clinical trials, doctors try new treatments and combinations to determine whether they work or not. They also study new ways to perform surgery or radiation therapy. Patients who agree to participate in skin cancer clinical trials may get access to treatments that would not otherwise be available to the general public. However, these trials are not without risks, and patients should be aware of these before agreeing to participate.
Clinical trials are necessary for the development of new treatments for a wide variety of conditions, including psoriasis. These studies require considerable funding and can take years to complete. Furthermore, they must be able to measure improvements in a patient’s quality of life. If the drug improves quality of life, it could be considered a valuable treatment option.
Several different clinical trials are currently taking place. In addition to examining the efficacy of various treatments for skin cancer, some of these studies aim to investigate the role of microbes in the development of skin disorders. For example, one study involving probiotic treatments for atopic dermatitis is being funded by the National Institutes of Health.
The goal of the clinical trials of these new drugs is to improve patient outcomes and quality of life. Since 2011, eight new therapies for melanoma have been approved by the FDA, including four targeted immunotherapy agents. Similarly, a recent focus in clinical research on psoriasis has focused on immunotherapy. Its progress has been impressive and has resulted in the approval of several new therapeutics. At present, half a dozen agents are in development.
Another study involves the creation of a repository of human biospecimens to study melanoma. This project also seeks to develop new methods of studying the native skin microflora and the effects of different ingredients on the microbiome.
